Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression

Acta Psychiatrica Scandinavica

Volumn 131, Issue 6, 2015, Pages 446-457

  Martiny, K ^a   Refsgaard, E ^b   Lund, V ^b   Lunde, M ^b   Thougaard, B ^b   Lindberg, L ^b   Bech, P ^b  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Chronotherapy; Depressive disorder; Light therapy; Randomized controlled trial; Sleep; Sleep deprivation

Indexed keywords

ANXIOLYTIC AGENT; BIPERIDEN; CITALOPRAM; CLONAZEPAM; DULOXETINE; FLUOXETINE; HALOPERIDOL; HYPNOTIC AGENT; LAMOTRIGINE; LITHIUM; MELATONIN; MIANSERIN; MIRTAZAPINE; MODAFINIL; OXAZEPAM; PREGABALIN; QUETIAPINE; SERTRALINE; VENLAFAXINE; ZOPICLONE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPOMANIA; INTERVENTION STUDY; KINESIOTHERAPY; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MIDDLE AGED; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SLEEP DISORDER; SLEEP QUALITY; SLEEP THERAPY; SLEEP TIME; SLEEP WAKING CYCLE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONOTHERAPY; DEPRESSIVE DISORDER, MAJOR; EXERCISE; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SELF EVALUATION; SLEEP;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG CHRONOTHERAPY; DULOXETINE HYDROCHLORIDE; EXERCISE; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; SELF-ASSESSMENT; SLEEP; TREATMENT OUTCOME;

EID: 84929131909     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12402     Document Type: Article

References (50)

1. Paykel ES. Partial remission, residual symptoms, and relapse in depression. Dialogues Clin Neurosci 2008;10:431-437.
2. Angst J, Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 1995;146:17-23.
3. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.
4. Mignon L, Stahl SM. Clinical management of major depressive disorder. CNS Spectr 2009;14(Suppl. 10):3-6.
5. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2010;71:43-64.
6. Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997-2011. Acta Psychiatr Scand 2014;6:417-426.
7. Miskowiak KW, Vinberg M, Christensen EM et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 2014;39:1399-1408.
8. McIntyre RS, Filteau MJ, Martin L et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014;156:1-7.
9. Rush AJ, Trivedi M, Carmody TJ et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004;56:46-53.
10. Sokero TP, Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Isometsä ET. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry 2005;186:314-318.
11. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Rep 2005;7:441-446.
12. Malhi GS, Kuiper S. Chronobiology of mood disorders. Acta Psychiatr Scand Suppl 2013;444:2-15.
13. Steinberg H, Hegerl U. Johann Christian August Heinroth on sleep deprivation as a therapeutic option for depressive disorders. Sleep Med 2014;15:1159-1164.
14. Goel N, Terman M, Terman JS, Macchi MM, Stewart JW. Controlled trial of bright light and negative air ions for chronic depression. Psychol Med 2005;35:945-955.
15. Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for affective disorders: a clinician's manual for light and wake therapy. Basel: S. Karger AG Switzerland, 2013:116.
16. Wu JC, Kelsoe JR, Schachat C et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009;66:298-301.
17. Benedetti F, Calabrese G, Bernasconi A et al. Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: a 3.0 Tesla study of bipolar depression. Psychiatry Res 2009;173:238-242.
18. Wu JC, Gillin JC, Buchsbaum MS et al. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry 1992;149:538-543.
19. Wirz-Justice A, Benedetti F, Berger M et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 2005;35:939-944.
20. Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother 2011;11:961-970.
21. Martiny K, Lunde M, Undén M, Dam H, Bech P. Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. Acta Psychiatr Scand 2005;112:117-125.
22. Martiny K, Lunde M, Undén M, Dam H, Bech P. High cortisol awakening response is associated with an impairment of the effect of bright light therapy. Acta Psychiatr Scand 2009;120:196-202.
23. Benedetti F, Riccaboni R, Locatelli C, Poletti S, Dallaspezia S, Colombo C. Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression. J Clin Psychiatry 2014;75:133-140.
24. Perroud N, Uher R, Marusic A et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009;15:60.
25. Cooney GM, Dwan K, Greig CA et al. Exercise for depression. Cochrane Database Syst Rev 2013;12:CD004366.
26. Krogh J, Videbech P, Thomsen C, Gluud C, Nordentoft M. DEMO-II trial. Aerobic exercise versus stretching exercise in patients with major depression-a randomised clinical trial. PLoS ONE 2012;7:e48316.
27. Krogh J, Nordentoft M, Sterne JAC, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2011;72:529-538.
28. Martiny K, Refsgaard E, Lund V et al. The day-to-day acute effect of wake therapy in patients with major depression using the HAM-D6 as primary outcome measure: results from a randomised controlled trial. PLoS ONE 2013;8:e67264.
29. Martiny K, Refsgaard E, Lund V et al. A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J Clin Psychiatry 2012;73:1234-1242.
30. EMEA. The European Agency for the evaluation of medicinal products. Note for guidance on Good Clinical Practice (CPMP/ICH/135/95). London: EMEA, 1997.
31. Terman M, Terman JS. Light therapy. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine, 5th edn. St. Louis, MO: Elsevier/Saunders, 2010:1682-1695.
32. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 1998;59:22-33.
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
34. Bech P. Clinical psychometrics. Oxford: Wiley-Blackwell, 2012.
35. O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997;95:379-384.
36. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106:252-264.
37. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord 2001;66:159-164.
38. Bech P. Measuring the dimensions of psychological general well-being by the WHO-5. QoL Newsletter 2004;32:15-16.
39. Olsen LR, Mortensen EL, Bech P. The SCL-92 validated by item response models in a Danish community sample. Acta Psychiatr Scand 2004;110:161-162.
40. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
41. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
42. Fekadu A, Wooderson S, Donaldson C et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009;70:177-184.
43. National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press (US), 2010.
44. Thabane L, Mbuagbaw L, Zhang S et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013;13:92.
45. Hedges LV, Olkin I. Statistical methods for meta-analysis. New York, NY: Academic Press, 1985:78-85.
46. Bech P, Olsen LR, Kjoller M, Rasmussen NK. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. Int J Methods Psychiatr Res 2003;12:85-91.
47. Ostergaard SD, Bech P, Trivedi MH et al. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). J Affect Disord 2014;163:18-24.
48. Bech P, Lauritzen L, Lunde M et al. Psychometric analysis of the Melancholia Scale in trials with non-pharmacological augmentation of patients with therapy-resistant depression. Acta Neuropsychiatr 2014;26:155-160.
49. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-1837.
50. Oldham MA, Ciraulo DA. Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system. Chronobiol Int 2014;31:305-319.